Blair Jackson

Stories

Alkermes unveils ADHD data for orexin drug, expanding the class beyond sleep disorders

As of September 2026: Leads orexin strategy; identified 19 potential applications

Alkermes presented its orexin agonist as an ADHD treatment on September 21, the first time the new drug class has moved into a mainstream psychiatric market. The company calls the program a potential 'company changer.'

Updated Sep 21